Gettinger S, Horn L, Jackman D et al (2018) Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: Results from the Ca209-003 study. J Clin Oncol 36(17):1675–1684. https://doi.org/10.1200/jco.2017.77.0412

Article  PubMed  CAS  Google Scholar 

Knight A, Karapetyan L, Kirkwood JM (2023) Immunotherapy in melanoma: Recent advances and future directions. Cancers (Basel) 15(4):1106. https://doi.org/10.3390/cancers15041106

Article  PubMed  CAS  Google Scholar 

Blumenthal GM, Zhang L, Zhang H et al (2017) Milestone analyses of immune checkpoint inhibitors, targeted therapy, and conventional therapy in metastatic non-small cell lung cancer trials: a meta-analysis. JAMA Oncol 3(8):e171029. https://doi.org/10.1001/jamaoncol.2017.1029

Article  PubMed  PubMed Central  Google Scholar 

Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor mutational burden and response rate to Pd-1 inhibition. N Engl J Med 377(25):2500–2501. https://doi.org/10.1056/NEJMc1713444

Article  PubMed  PubMed Central  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for Pd-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833. https://doi.org/10.1056/NEJMoa1606774

Article  PubMed  CAS  Google Scholar 

VanderWalde A, Bellasea SL, Kendra KL et al (2023) Ipilimumab with or without Nivolumab in Pd-1 or Pd-L1 blockade refractory metastatic melanoma: A randomized phase 2 trial. Nat Med 29(9):2278–2285. https://doi.org/10.1038/s41591-023-02498-y

Article  PubMed  PubMed Central  CAS  Google Scholar 

Moeckel C, Bakhl K, Georgakopoulos-Soares I et al (2023) The Efficacy of tumor mutation burden as a biomarker of response to immune checkpoint inhibitors. Int J Mol Sci 24(7):6710. https://doi.org/10.3390/ijms24076710

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dong ZY, Zhong WZ, Zhang XC et al (2017) Potential Predictive Value of Tp53 and kras mutation status for response to Pd-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res 23(12):3012–3024. https://doi.org/10.1158/1078-0432.Ccr-16-2554

Article  PubMed  CAS  Google Scholar 

Dong Y, Zhao L, Duan J et al (2022) Pappa2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer. Cell Prolif 55(9):e13283. https://doi.org/10.1111/cpr.13283

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chudnovsky Y, Kim D, Zheng S et al (2014) Zfhx4 interacts with the nurd Core Member Chd4 and regulates the glioblastoma tumor-initiating cell state. Cell Rep 6(2):313–324. https://doi.org/10.1016/j.celrep.2013.12.032

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zong S, Xu PP, Xu YH et al (2022) A bioinformatics analysis: Zfhx4 is associated with metastasis and poor survival in ovarian cancer. J Ovarian Res 15(1):90. https://doi.org/10.1186/s13048-022-01024-x

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ha M, Kim J, Park SM et al (2020) Prognostic role of zinc finger homeobox 4 in ovarian serous cystadenocarcinoma. Genet Test Mol Biomarkers 24(3):145–149. https://doi.org/10.1089/gtmb.2019.0185

Article  PubMed  CAS  Google Scholar 

Qing T, Zhu S, Suo C et al (2017) Somatic mutations in Zfhx4 gene are associated with poor overall survival of chinese esophageal squamous cell carcinoma patients. Sci Rep 7(1):4951. https://doi.org/10.1038/s41598-017-04221-7

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hellmann MD, Nathanson T, Rizvi H et al (2018) Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell 33(5):843-852.e844. https://doi.org/10.1016/j.ccell.2018.03.018

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rizvi NA, Hellmann MD, Snyder A et al (2015) Cancer immunology. Mutational landscape determines sensitivity to Pd-1 blockade in non-small cell lung cancer. Science 348(6230):124–128. https://doi.org/10.1126/science.aaa1348

Article  PubMed  PubMed Central  CAS  Google Scholar 

Miao D, Margolis CA, Vokes NI et al (2018) Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet 50(9):1271–1281. https://doi.org/10.1038/s41588-018-0200-2

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hoadley KA, Yau C, Hinoue T et al (2018) Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173(2):291-304.e296. https://doi.org/10.1016/j.cell.2018.03.022

Article  PubMed  PubMed Central  CAS  Google Scholar 

Charoentong P, Finotello F, Angelova M et al (2017) Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 18(1):248–262. https://doi.org/10.1016/j.celrep.2016.12.019

Article  PubMed  CAS  Google Scholar 

Thorsson V, Gibbs DL, Brown SD et al (2018) The immune landscape of cancer. Immunity 48(4):812-830.e814. https://doi.org/10.1016/j.immuni.2018.03.023

Article  PubMed  PubMed Central  CAS  Google Scholar 

Roh W, Chen PL, Reuben A et al (2017) Integrated Molecular Analysis of Tumor Biopsies on Sequential Ctla-4 and Pd-1 Blockade Reveals Markers of Response and Resistance. Sci Transl Med 9(379):eaah3560. https://doi.org/10.1126/scitranslmed.aah3560

Article  PubMed  PubMed Central  CAS  Google Scholar 

Riaz N, Havel JJ, Makarov V et al (2017) Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171(4):934-949.e916. https://doi.org/10.1016/j.cell.2017.09.028

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liu D, Schilling B, Liu D et al (2019) Integrative molecular and clinical modeling of clinical outcomes to pd1 blockade in patients with metastatic melanoma. Nat Med 25(12):1916–1927. https://doi.org/10.1038/s41591-019-0654-5

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hugo W, Zaretsky JM, Sun L et al (2016) Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma. Cell 165(1):35–44. https://doi.org/10.1016/j.cell.2016.02.065

Article  PubMed  PubMed Central  CAS  Google Scholar 

Miao W, Li L, Wang Y (2018) A targeted proteomic approach for heat shock proteins reveals dnajb4 as a suppressor for melanoma metastasis. Anal Chem 90(11):6835–6842. https://doi.org/10.1021/acs.analchem.8b00986

Article  PubMed  PubMed Central  CAS  Google Scholar 

Van Allen EM, Miao D, Schilling B et al (2015) Genomic correlates of response to ctla-4 blockade in metastatic melanoma. Science 350(6257):207–211. https://doi.org/10.1126/science.aad0095

Article  PubMed  PubMed Central  CAS  Google Scholar 

Samstein RM, Lee CH, Shoushtari AN et al (2019) Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51(2):202–206. https://doi.org/10.1038/s41588-018-0312-8